Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Apple Turns 50: From Garage Startup to AI Crossroads 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Britain Courts Anthropic Amid US Defense Department Dispute 
TEMPLE CITY, Calif., Oct. 07, 2016 -- Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent Genetics” or the “company”) announced today that the underwriters of its previously announced initial public offering have exercised in full their option to purchase 630,000 additional shares of the company’s common stock at a public offering price of $9.00 per share, before underwriting discounts. All of the additional shares were offered by Fulgent Genetics.
Credit Suisse Securities (USA) LLC and Piper Jaffray & Co. acted as joint book-running managers for the offering. Raymond James & Associates, Inc. acted as lead manager and BTIG, LLC acted as co-manager.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 28, 2016. The offering was made solely by means of a prospectus. A copy of the final prospectus relating to this offering may be obtained from: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, New York, NY 10010, by telephone at +1-800-221-1037, or by email at [email protected]; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Suite 800, Minneapolis, MN 55402, by telephone at +1-800-747-3924, or by email at [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
IR Contacts: Bob Jones 212-871-5570 [email protected] Chris Danne 415-217-5865 [email protected]
